Wednesday, 29 March 2023

Why Intra-Cellular Therapies Climbed Tuesday

by Earn Media

What happened

Shares of Intra-Cellular Therapeutics (NASDAQ: ITCI) were up 14.8% Tuesday morning after the healthcare company released top-line phase 3 trial information regarding its depression therapy, Caplyta (lumateperone). The drug, administered in a 42-milligram daily dose, met its primary endpoint of a reduction of symptoms on the Montgomery Asberg Depression Rating Scale (MADRS), the company said.

The stock is down more than 12% over the past 12 months but up more than 2% so far in 2023.

So what

Intra-Cellular focuses on therapies to treat central nervous system disorders. The key in the study was Caplyta did well on patients with major depressive disorder (MDD) with mixed features, as well as bipolar depression with mixed features.

Overall, patients saw a 5.7-point reduction on the MADRS 60-point scale of depression severity. The study could mean a big jump up in patients for Caplyta, which is approved to treat schizophrenia as well as episodes of bipolar I and bipolar II depression.

The antipsychotic drug was responsible for most of the company’s revenue last year, bringing in $249.1 million, up 205% over 2021. Overall, the biotech company’s revenue rose 199% last year to $250.3 million.

Now what

While Intra-Cellular has four drugs in its pipeline, Caplyta is its only drug approved by the Food and Drug Administration (FDA). Adding MDD as well as patients with depression tied to MDD and bipolar depression would significantly increase its patient population.

According to the National Institute of Mental Health (NIMH), there were 21 million adults in the U.S. in 2020 with at least one major depressive episode. Bipolar disorder affects roughly 5.7 million people in the U.S., according to the NIMH. Last year, the company reported a loss of $256.3 million, or $2.72 a share, compared to a loss of $284.1 million, or $3.50 a share, in 2021. The addition of more indications for Caplyta could push the company’s finances into the black.

10 stocks we like better than Intra-Cellular Therapies
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now… and Intra-Cellular Therapies wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of March 8, 2023

Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.